Concepts of tumor lectinology

Cancer Investigation

Volumn 15, Issue 5, 1997, Pages 454-464

  Gabius, Hans Joachim ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOCONJUGATE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; LECTIN; TUMOR NECROSIS FACTOR ALPHA;

CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CELL TRANSFORMATION; ENDOCYTOSIS; GLYCOSYLATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LIPID ANALYSIS; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; TUMOR CELL;

EID: 0030766193     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909709047585     Document Type: Review

References (129)

1. Hounsell EF, ed: Glycoprotein Analysis in Biomedicine. Meth Mol Biol, Vol 14, Totowa, NJ, Humana Press, 1993.
2. Dwek RA, Edge CJ, Harvey DJ, et al: Analysis of glycoprotein-associated oligosaccharides. Annu Rev Biochem 62:65-100, 1993.
3. Montreuil J, Vliegenthart JFG, Schachter H, eds: Glycoproteins, Amsterdam, Elsevier, 1995.
4. Kobata A: Structures and functions of the sugar chains of glycoproteins. Eur J Biochem 209:483-501, 1992.
5. Lis H, Sharon N: Protein glycosylalion. Structural and functional aspects. Eur J Biochem 218:1-27, 1993.
6. Laine RA: The information-storing potential of the sugar code. In: Glycosciences: Status and Perspectives, edited by HJ Gabius, S Gabius, London, Chapman & Hall, 1997, pp. 1-14.
7. Varki A: Biological roles of oligosaccharides: All of the theories are correct. Glycobiology 3:97-130, 1993.
8. Baenziger JU: Protein-specific glycosyltransferases: How and why they do it. FASEB J 8:1019-1025, 1994.
9. Spicer SS, Schulte BA: Diversity of cell glycoconjugates shown histochemically: A perspective. J Histochem Cytochem 40:1-38, 1992.
10. Gabius HJ, Gabius S, eds: Lectins and Glycobiology, Heidelberg, Springer, 1993.
11. Vijayakumar T, Remani P, Ankathil R, et al: Plant lectins in immunology, cytology and hematology: A bibliography and projects for development Hematol Rev 8:151-168, 1994.
12. Danguy A: Perspectives in modern glycohistochemistry. Eur J Histochem 39:5-14, 1995.
13. Alhadeff JA: Malignant cell glycoproteins and glycolipids. CRC Crit Rev Oncol/Hematol 9:37-107, 1989.
14. Hakomori S: Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res 52:257-331, 1989.
15. Walker RA: The use of lectins in histopathology. Pathol Res Pract 185:826-835, 1989.
16. Sell S: Cancer-associated carbohydrates identified by monoclonal antibodies. Hum Pathol 21:1003-1019, 1990.
17. Gabius HJ, Gabius S, eds: Lectins and Cancer, Heidelberg, Springer, 1991.
18. Muramatsu T: Carbohydrate signals in metastasis and prognosis of human carcinomas. Glycobiology 3:291-296, 1993.
19. Mody R, Joshi SS, Chancy W: The use of lectins as diagnostic and therapeutic tool for cancer. J Pharmacol Toxicol Meth 33:1-10, 1995.
20. Barondes SH: Bifunctional properties of lectins: lectins redefined. Trends Biochem Sci 13:480-482, 1988.
21. Gabius HJ: Vertebrate lectins and their possible roles in fertilization, development and tumor biology. In Vivo 1:75-84, 1987.
22. Sharon N, Lis H: Lectins as cell recognition molecules. Science 246:227-234, 1989.
23. Gabius HJ: Detection and functions of mammalian lectins - With emphasis on membrane lectins. Biochim Biophys Acta 1071:1-18, 1991.
24. Powell LD, Varki A: I-type lectins. J Biol Chem 270:14243-14246, 1995.
25. Zanetta JP: Lectins and carbohydrates in animal cell adhesion and control of proliferation. In: Glycosciences: Status and Perspectives, edited by HJ Gabius, S Gabius, London, Chapman & Hall, 1997, pp. 439-458.
26. Gabius HJ: Endogenous lectins in tumors and the immune system. Cancer Invest 5:39-46, 1987.
27. Krantz MJ, Hollzman NA, Stowell CP, et al: Attachment of thioglycosides to proteins: Enhancement of liver membrane binding. Biochemistry 15:3963-3968, 1976.
28. Stowell CP, Lee YC: Neoglycoproteins: The preparation and application of synthetic glycoproteins. Adv Carbohydr Chem Biochem 37:225-281, 1981.
29. Lee YC, Lee RT, eds: Neoglycoconjugates. Preparation and Applications, San Diego, Academic Press, 1994.
30. Danguy A, Kayser K, Bovin NV, et al: The relevance of neoglycoconjugates for histology and pathology. Trends Glycosci Glycotechnol 7:261-275, 1995.
31. Bovin NV, Gabius HJ: Polymer-immobilized carbohydrate ligands: Versatile chemical tools for biochemistry and medical sciences. Chem Soc Rev 24:413-421, 1995.
32. Gabius HJ, Gabius S, Zemlyanukhina TV, et al: Reverse lectin histochemistry: Design and application of glycoligands for detection of cell and tissue lectins. Histol Histopathol 8:369-383, 1993.
33. Monsigny M, Roche AC, Midoux P, et al: Endogenous lectins of myeloid and tumor cells: Characterization and biological implications. In: Lectins and Glycoconjugates in Oncology, edited by HJ Gabius, GA Nagel, Heidelberg, Springer, 1988, pp. 25-47.
34. Gabius HJ, Gabius S: Chemical and biochemical strategies for the preparation of glycohistochemical probes and their application in lectinology. Adv Lectin Res 5:123-157, 1992.
35. Midoux P, Roche AC, Monsigny M: Estimation of the degradation of endocytosed material by flow cytofluorometry using two neoglycoproteins containing different numbers of fluorescein molecules. Biol Cell 58:221-226, 1986.
36. Gabius HJ, André S, Danguy A, et al: Detection and quantification of carbohydrate-binding sites on cell surfaces and in tissue sections by neoglycoproteins. Meth Enzymol 242:37-46, 1994.
37. Gabius HJ: Tumor lectinology: At the intersection of carbohydrate chemistry, biochemistry, cell biology and oncology. Angew Chem Int Ed Eng 27:1267-1276, 1988.
38. Monsigny M, Roche AC, Midoux P, et al: Glycoconjugates as carriers for specific drug delivery of therapeutic drugs and genes. Adv Drug Deliv Rev 14:1-24, 1994.
39. Molema G, Meijer DKF: Targeting of drugs to various blood cell types using neoglycoproteins, antibodies and other carrier proteins. Adv Drug Deliv Rev 14:25-50, 1994.
40. Seymour LW: Soluble polymers for lectin-mediated drug targeting. Adv Drug Deliv Rev 14:89-111, 1994.
41. Frese J, Wu CH, Wu GY: Targeting of genes to the liver with glycoprotein carriers. Adv Drug Deliv Rev 14:137-152, 1994.
42. Wadhwa MS, Rice KG: Receptor-mediated glycotargeting. J Drug Targ 3:111-127, 1995.
43. Kayser K, Bovin NV, Zemlyanukhina TV, et al: Cell type-dependent alterations of binding of synthetic blood group antigen-related oligosaccharides in lung cancer. Glycoconjugate J 11:339-344, 1994.
44. + T-cell subsets. Proc Natl Acad Sci USA 91:18-22, 1994.
45. y antigen expression is correlated with apoptosis (programmed cell death). Glycobiology 3:381-390, 1993.
46. Lotan R, Raz A: Endogenous lectins as mediators of tumor cell adhesion. J Cell Biochem 37:107-117, 1988.
47. Gabius S, Schirrmacher V, Franz H, et al: Analysis of cell surface sugar receptor expression by neoglycoenzyme binding and adhesion to plastic-immobilized neoglycoproteins for related weakly and strongly melaslatic cell lines of murine tumor model systems, Int J Cancer 46:500-507, 1990.
48. Gabius S, Wawotzny R, Wilholm S, et al: Adhesion of human lymphoid cell lines to immobilized carbohydrates and to bone marrow stromal cell layers by surface sugar receptors. Int J Cancer 54:1017-1021, 1993.
49. Seshi B: Discovery of novel hematopoietic cell adhesion molecules from human bone marrow stromal cell membrane protein extracts by a new cell-blotting technique. Blood 83:2399-2409, 1994.
50. Inohara H, Raz A: Functional evidence that cell surface galectin-3 mediates homotypic cell adhesion. Cancer Res 55:3267-3271, 1995.
51. White TK, Zhu Q, Tanzer ML: Cell surface calreticulin is a putative mannoside lectin which triggers mouse melanoma cell spreading. J Biol Chem 270:15926-15929, 1995.
52. Nangia-Makker P, Thompson E, Hogan C, et al: Induction of tumorigenicity by galectin-3 in a non-tumorigenic human breast carcinoma cell line. Int J Oncol 7:1079-1087, 1995.
53. Oguchi H, Toyokuni T, Dean B, et al: Effect of lactose derivatives on metastatic potential of B16 melanoma cells. Cancer Commun 2:311-316, 1990.
54. Woynarowska B, Skrincosky DM, Haag A, et al: Inhibition of lectin-mediated ovarian tumor cell adhesion by sugar analogs. J Biol Chem 269:22797-22803, 1994.
55. Pienta KJ, Naik H, Akhtar A, et al: Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst 87:348-353, 1995.
56. Cornil I, Kerbel RS, Dennis JW: Tumor cell surface β1-4-linked galactose binds to lectin(s) on microvascular endothelial cells and contributes io organ colonization. J Cell Biol 111:773-781, 1990.
57. Lotan R, Belloni PN, Tressler RJ, et al: Expression of galectins on microvessel endothelial cells and their involvement in tumor cell adhesion. Glycoconjugate J 11:462-468, 1994.
58. Welply JK, Keene JL, Schmuke JJ, et al: Selectins as potential targets of therapeutic intervention in inflammatory disease. Biochim Biophys Acta 1197:215-226, 1994.
59. Lasky CA: Selectin-carbohydrate interactions and the initiation of the inflammatory response. Annu Rev Biochem 64:113-139, 1995.
60. Plendl J, Sinowatz F, Auerbach R, et al: Quantitative differences in neoglycoprotein binding for vascular endothelial cells from porcine brain, ovary and testis in vitro. Microvasc Res 50:199-214, 1995.
61. Dintzis RZ, Okajima M, Middleton MH, et al: The immunogenicity of soluble haptenated polymers is determined by molecular mass and hapten valence. J Immunol 143:1239-1244, 1989.
62. Livingston PO: Construction of cancer vaccines with carbohydrate and protein (peptide) tumor antigens. Curr Opinion Immunol 4:624-629, 1992.
63. MacLean GD, Reddish MA, Bowen-Yacyshyn MB, et al: Active specific immunotherapy against adenocarcinomas. Cancer Invest 12:46-56, 1994.
64. Gabius HJ, Bardosi A: Neoglycoproleins as tools in glycohistochemistry. Progr Histochem Cytochem 22:1-66, 1991.
65. Raz A, Meromsky L, Zvibel I, et al: Transformation-related changes in the expression of endogenous cell lectins. Int J Cancer 39:353-360, 1987.
66. Gabius S, Hellmann KP, Ciesiolka T, et al: Lineageand differentiation-dependent alterations in the expression of receptors for glycoconjugates (lectins) in different human hematopoietic cell lines and low grade lymphomas. Blut 59:165-170, 1989.
67. Lotan R, Lotan D, Carralero DM: Modulation of galacloside-binding lectins in tumor cells by differentiation-inducing agents. Cancer Lett 48:115-122, 1989.
68. Gabius S, Yamazaki N, Hanewacker W, et al: Regulation of distribution, amount and ligand affinity of sugar receptors in human colon carcinoma cells by treatment with sodium butyrate, retinoic acid and phorbol ester. Anticancer Res 10:1005-1012, 1990.
69. Gabius HJ, Gabius S, Pritsche M, et al: Transformation-associated decrease in cell surface binding of neoglycoenzymes in a temperature-sensitive, virally transformed mouse model. Naturwissenschaften 78:230-232, 1991.
70. Vidal-Vanaclocha F, Barbera-Guillem E, Weiss L, et al: Quantitation of endogenous lectin expression in 3LL tumors, growing subcutaneously and in the kidneys of mice. Int J Cancer 46:908-912, 1990.
71. Gabius HJ, Brehler R, Schauer A, et al: Localization of endogenous lectins in normal human breast, benign breast lesions and mammary carcinomas. Virch Arch [Cell Pathol] 52:107-115, 1986.
72. Irimura T, Matsushita Y, Sutton RC, et al: Increased content of an endogenous lactose-binding lectin in human colorectal carcinoma progressed to metastatic stages. Cancer Res 51:387-393, 1991.
73. Lotan R, Ho H, Yasui W, et al: Expression of a 31-kDa lactose-binding lectin in normal human gastric mucosa and in primary and metastatic gastric carcinomas. Int J Cancer 56:474-480, 1994.
74. Chiarotti L, Berlingieri MT, Battaglia C, et al: Expression of galectin-1 in normal human thyroid gland and in differentiated and poorly differentiated thyroid tumors. Int J Cancer 64:171-175, 1995.
75. Schoeppner HL, Raz A, Ho SB, et al: Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer 75:2818-2826, 1995.
76. Xu XC, El-Naggar AK, Lotan R: Differential expression of galectin-1 and galectin-3 in thyroid tumors. Am J Pathol 147:815-822, 1995.
77. Ohannesian DW, Lotan D, Lotan R: Concomitant increases of galectin-1 and its glycoprotein ligands (carcinoembryonic antigen, Lamp-1, and Lamp-2) in cultured human colon carcinoma cells by sodium butyrate. Cancer Res 54:5992-6000, 1994.
78. Ohannesian DW, Lotan D, Thomas P, et al: Carcinoembryonic antigen and other glycoconjugates act as ligands for galectin-3 in human colon carcinoma cells. Cancer Res 55:2191-2199, 1995.
79. Gabius HJ, Kohnke-Godt B, Leichsenring M, et al: Heparin-binding lectin of human placenta as a tool for histochemical ligand localization and ligand isolation. J Histochem Cytochem 39:1249-1256, 1991.
80. Sleat DE, Chen TL, Raska K, et al: Increased levels of glycoproteins containing mannose-6-phosphate in human breast carcinomas. Cancer Res 55:3424-3430, 1995.
81. Dube VE: The structural relationship of blood group-related oligosaccharides in human carcinomas to biological function: A perspective. Cancer Metast Rev 6:541-557, 1987.
82. Hakomori S: Possible functions of tumor-associated carbohydrate antigens. Curr Opin Immunol 3:646-653, 1991.
83. King MJ: Blood group antigens on human erythrocytes: distribution, structure and possible functions. Biochim Biophys Acta 1197:15-44, 1994.
84. Orntoft TF, Bech E: Circulating blood group-related carbohydrate antigens as tumor markers. Glycoconjugate J 12:200-205, 1995.
85. Kayser K, Bovin NV, Korchagina EY, et al: Correlation of expression of binding sites for synthetic blood group A-, B-, and H-trisaccharides and for sarcolectin with survival of patients with bronchial carcinoma. Eur J Cancer 30A:653-657, 1994.
86. Kayser K, Bovin NV, Zeng FY, et al: Binding capacities to blood-group antigens A, B, and H, DNA- and MST measurements, and survival in bronchial carcinoma. Radiol Oncol 28:282-286, 1994.
87. Kayser K, Bubenzer J, Kayser G, et al: Expression of lectin-, interleukin-2-, and histo-blood group-binding sites in prostate cancer and its correlation with integrated optical density and syntactic structure analysis. Analyt Quant Cytol Histol 17:135-142, 1995.
88. Miyake M, Hakomori S: A specific cell surface glycoconjugate controlling cell motility: Evidence by functional monoclonal antibodies that inhibit cell motility and tumor cell metastasis. Biochemistry 30:3328-3334, 1990.
89. Bryne M, Thrane PS, Dabelsteen E: Loss of expression of blood group antigen H is associated with cellular invasion and spread of oral squamous cell carcinomas. Cancer 67:613-618, 1991.
90. b-antigens with survival in patients with carcinoma of the lung. N Engl J Med 327:14-18, 1992.
91. Santos-Benito FF, Fernandez-Mayoralas A, Martin-Lomas M, et al: Inhibition of proliferation of normal and transformed neural cells by blood group-related oligosaccharides. J Exp Med 176:915-918, 1991
92. Ogawa J, Inoue H, Koida S: Prognostic significance of Lewis x-related antigen expresison in stage I non-small cell lung cancer. Eur J Cancer 31A:1716, 1995.
93. Gabius HJ: Lectinology meets mythology: Oncological future for the mistletoe lectin? Trends Glycosci Glycotechnol 6:229-238, 1994.
94. Gabius HJ, Gabius S, Joshi SS, et al: From ill-defined extracts to the immunodulatory lectin: Will there be a reason for oncological application of mistletoe? Planta Med 60:2-7, 1994.
95. Gabius HJ, Walzel H, Joshi SS, et al: The immunomodulatory galactoside-specific lectin from mistletoe: Partial sequence analysis, cell and tissue binding, and impact on intracellular biosignalling of monocytic leukemia cells. Anticancer Res 12:669-676, 1992.
96. Kajikawa T, Nakajima Y, Hirabayashi J, et al: Release of cytotoxin by macrophages on treatment with human placenta lectin. Life Sci 39:1177-1181, 1986.
97. Jeng KCG, Frigeri LG, Liu FT: An endogenous lectin, galectin-3 (εBP/MAC-2), potentiates IL-1 production by human monocytes. Immunol Lett 42:113-116, 1994.
98. Timoshenko AV, Kayser K, Drings P, et al: Modulation of lectin-triggered superoxide release from neutrophils of tumor patients with and without chemotherapy. Anticancer Res 13:1789-1792, 1993.
99. Yamaoka A, Kuwabara I, Frigeri LG, et al: A human lectin, galectin-3 (εBP/MAC-2), stimulates superoxide production by neutrophils. J Immunol 154:3479-3487, 1995.
100. Michiel DF, Oppenheim JJ: Cytokines as positive and negative regulators of tumor promotion and progression. Semin Cancer Biol 3:3-15, 1992.
101. Neidhart JA: Hematopoietic cytokines. Current use in cancer therapy. Cancer 72:3381-3386, 1993.
102. Ravoet C, De Greve J, Vandewoude K, et al: Tumor stimulating effects of recombinant human interleukin-6. Lancet 344:1576-1577, 1994.
103. Chambers SK, Wang Y, Gertz RE, et al: Macrophage colony-stimulating factor mediates invasion ot ovarian cancer cells through urokinase. Cancer Res 55:1578-1585, 1995.
104. Hilbert DM, Kopf M, Mock BA, et al: Interleukin-6 is essential for in vivo development of B lineage neoplasms. J Exp Med 182:243-248, 1995.
105. Spiekermann K, O'Brien S, Esley E: Relapse of acute myelogenous leukemia during low dose interleukin-2 therapy. Cancer 75:1594-1597, 1995.
106. Fitzpatrick DR, Manning LS, Musk AW, et al: Potential for cylokine treatment of malignant mesothelioma. Cancer Treat Rev 21:273-288, 1995.
107. Zeng FY, Weiser WY, Kratzin H, et al: The major binding protein of the interferon antagonist sarcolectin in human placenta is a macrophage migration inhibitory factor. Arch Biochem Biophys 303:74-80, 1993.
108. Sherblom AP, Sathyamoorthy N, Decker JM et al: IL-2, a lectin with specificity for high mannose glycopeptides. J Immunol 143:939-944, 1989.
109. Gearing AJH, Newman W: Circulating adhesion molecules. Immunol Today 14:506-512, 1993.
110. Lucas R, Magez S, De Leys R, et al: Mapping the lectin-like activity of tumor necrosis factor. Science 263:814-817, 1994.
111. x oligosaccharide inhibiting L-selectin-dependent lymphocyte adhesion. J Exp Med 182:1133-1142, 1995.
112. Adler P, Wood SJ, Lee YC, et al: High affinity binding of the Entamoeba histolytica lectin to polyvalent N-acetylgalactosaminides. J Biol Chem 270:5164-5171, 1995.
113. Karlsson KA: Microbial recognition of target-cell glycoconjugates. Curr Opin Struct Biol 5:622-635, 1995.
114. Bertozzi C: Cracking the carbohydrate code for selectin recognition. Chem Biol 2:703-708, 1995.
115. Gabius HJ, Kayser K, Gabius S: Protein-Zucker-Erkennung. Naturwissenschaften 82:533-543, 1995.
116. Toyokuni T, Singhai AK: Synthetic carbohydrate vaccines based on tumor-associated antigens. Chem Soc Rev 24:231-242, 1995.
117. Chambers WH, Adamkiewicz T, Houchins JP: Type II integral membrane proteins with characteristics of C-type animal lectins expressed by natural killer (NK) cells. Glycobiology 3:9-14, 1993.
118. Bezouska K, Yuen CT, O'Brien J, et al: Oligosaccharide ligands for NKR-P1 protein activate NK cells and cytotoxicity. Nature 372:150-157, 1994.
119. d, has a functional carbohydrate recognition domain. Immunity 1:785-792, 1994.
120. Kawakami K, Yamamoto K, Toyoshima S, et al: Dual function of macrophage galactose/N-acetylgalactosamine-specific lectins: Glycoprotein uptake and tumoricidal cellular recognition. Jpn J Cancer Res 85:744-749, 1994.
121. Lanier LL, Chang C, Phillips JH: Human NKR-P1A. A disulfide-linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes. J Immunol 153:2417-2428, 1994.
122. Brennan J, Takei F, Wong S, et al: Carbohydrate recognition by a natural killer cell receptor, Ly-49C. J Biol Chem 270:9691-9694, 1995.
123. Chambers WH, Brisette-Storkus CS: Hanging in the balance: Natural killer cell recognition of target cells. Chem Biol 2:429-435, 1995.
124. Ryan JC, Niemi EC, Nakamura MC, et al: NKR-P1A is a target-specific receptor that activates natural killer cell cytotoxicity. J Exp Med 181:1911-1915, 1995.
125. Yokoyama WM: Hybrid resistance and the Ly-49 family of natural killer cell receptors. J Exp Med 182:273-277, 1995.
126. Gabius HJ, Gabius S, eds: Glycosciences: Status and Perspectives, London, Chapman & Hall, 1997.
127. Stent G: That was the molecular biology that was. Science 160:390-395, 1968.
128. Kawade Y: Four stages in the history of interferon research. J Interfer Res 7:461-465, 1987.
129. Krown SE: Interferons in malignancy: Biological products or biological response modifiers? J Natl Cancer Inst 80:306-309, 1988.